Over the last year we have seen the beginning of commoditization process for the two major cannabinoids and the words ‘race to the bottom’ are often mentioned with regards to THC and CBD prices.
‘Secondary metabolites’ are compounds made by a plant but not essential for its survival. In cannabis, a large part of this array of compounds are synthesized in dedicated ‘mini-organs’, the trichomes. Trichomes are a remarkable adaptation that allows the plant to sequester secondary metabolites at high concentrations (3). They enable the plant to produce compounds, which in high concentrations, may be toxic to cells in other tissues, and use this accumulation mechanism to protect the reproductive tissues of the plant.
Yet cannabinoids, common or rare, make up only a fraction of the rich diversity of secondary metabolites produced by the plant and the full spectrum includes unique mono/sesqui -terpenes, flavonoids, pigments and other molecule families with diverse structures. With more than 150 cannabinoids identified so far and grouped into families based on their chemical backbone (9) ,twelve molecules are the ‘major cannabinoids’, present in most cannabis or hemp cultivars at varying ratios and others usually accumulate in lower quantities and are produced by alternations of enzymatic and non-enzymatic reactions.
The therapeutic properties of cannabis are mostly attributed to cannabinoids yet a growing body of evidence exits to support the ‘entourage effect’ ((1),(4),(8)) in which the synergy between compounds from different chemical families is superior to the effect of isolated cannabinoids (in any ratio). Isolated compound, such as CBDA/THCA or the other ‘major cannabinoids’, are becoming commoditized as API’s (active pharmaceutical ingredients) and to some extent are very likely to be produced by semi-synthetic systems or full chemical synthesis. The complex nature of the interactions between a mix of compounds (plant extracts) makes the study of their effect very complex (this is the case for uncharacterized mixtures of known compounds, unidentified active ingredients, or identified compounds that are too complex for cost-effective synthesis). This shortcoming gives an advantage to plant-based systems over isolated compounds.
As summarized in the flowchart below, value for specific cultivars will be generated through collection of data (clinical, pre-clinical and bulk data collected from multiple users on a specific strain) and through partnering with academics and clinicians that generate cultivar -specific data from standardized full plant extracts.
NRGene offers tools to both explore biosynthesis pathways for production of secondary metabolites outside of the plant (using plant genes), or for enhancing productivity, agricultural performance and robustness of strains that already achieved consumer-demand through clinical studies or through reputation with patients.
We want to hear more about your needs. Please fill the form below and member of our team will contact you in the next few days.